1,302
Views
0
CrossRef citations to date
0
Altmetric
Research Article

Long-term treatment for endometriosis with dienogest: efficacy, side effects and tolerability

, , , , , & show all
Article: 2336121 | Received 01 Feb 2024, Accepted 22 Mar 2024, Published online: 05 Apr 2024

References

  • Bulun SE, Yilmaz BD, Sison C, et al. Endometriosis. Endocr Rev. 2019;40(4):1–7. doi: 10.1210/er.2018-00242.
  • Vannuccini S, Reis FM, Coutinho LM, et al. Surgical treatment of endometriosis: prognostic factors for better quality of life. Gynecol Endocrinol. 2019;35(11):1010–1014. doi: 10.1080/09513590.2019.1616688.
  • Saunders PTK, Horne AW. Endometriosis: etiology, pathobiology, and therapeutic prospects. Cell. 2021;184(11):2807–2824. doi: 10.1016/j.cell.2021.04.041.
  • Chapron C, Marcellin L, Borghese B, et al. Rethinking mechanisms, diagnosis and management of endometriosis. Nat Rev Endocrinol. 2019;15(11):666–682. doi: 10.1038/s41574-019-0245-z.
  • Capezzuoli T, Rossi M, La Torre F, et al. Hormonal drugs for the treatment of endometriosis. Curr Opin Pharmacol. 2022;67:102311. doi: 10.1016/j.coph.2022.102311.
  • Vannuccini S, Clemenza S, Rossi M, et al. Hormonal treatments for endometriosis: the endocrine background. Rev Endocr Metab Disord. 2022;23(3):333–355. doi: 10.1007/s11154-021-09666-w.
  • Reis FM, Coutinho LM, Vannuccini S, et al. Progesterone receptor ligands for the treatment of endometriosis: the mechanisms behind therapeutic success and failure. Hum Reprod Update. 2020;26(4):565–585. doi: 10.1093/humupd/dmaa009.
  • Grandi G, Mueller M, Bersinger NA, et al. Does dienogest influence the inflammatory response of endometriotic cells? A systematic review. Inflamm Res. 2016;65(3):183–192. doi: 10.1007/s00011-015-0909-7.
  • Miyashita M, Koga K, Takamura M, et al. Dienogest reduces proliferation, aromatase expression and angiogenesis, and increases apoptosis in human endometriosis. Gynecol Endocrinol. 2014;30(9):644–648. doi: 10.3109/09513590.2014.911279.
  • Strowitzki T, Marr J, Gerlinger C, et al. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–641. doi: 10.1093/humrep/dep469.
  • Cho B, Roh J-W, Park J, et al. Safety and effectiveness of dienogest (visanne®) for treatment of endometriosis: a large prospective cohort study. Reprod Sci. 2020;27(3):905–915. doi: 10.1007/s43032-019-00094-5.
  • Petraglia F, Hornung D, Seitz C, et al. Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment. Arch Gynecol Obstet. 2012;285(1):167–173. doi: 10.1007/s00404-011-1941-7.
  • Barra F, Scala C, Leone Roberti Maggiore U, et al. Long-Term administration of dienogest for the treatment of pain and intestinal symptoms in patients with rectosigmoid endometriosis. J Clin Med. 2020;9(1):154. doi: 10.3390/jcm9010154.
  • Ceccaroni M, Clarizia R, Liverani S, et al. Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial. Gynecol Endocrinol. 2021;37(10):930–933. doi: 10.1080/09513590.2021.1929151.
  • Uludag SZ, Demirtas E, Sahin Y, et al. Dienogest reduces endometrioma volume and endometriosis-related pain symptoms. J Obstet Gynaecol. 2021;41(8):1246–1251. doi: 10.1080/01443615.2020.1867962.
  • Capezzuoli T, Vannuccini S, Mautone D, et al. Long-term hormonal treatment reduces repetitive surgery for endometriosis recurrence. Reprod Biomed Online. 2021;42(2):451–456. doi: 10.1016/j.rbmo.2020.09.018.
  • Maiorana A, Maranto M, Restivo V, et al. Evaluation of long-term efficacy and safety of dienogest in patients with chronic cyclic pelvic pain associated with endometriosis. Arch Gynecol Obstet. 2024;309(2):589–597. doi: 10.1007/s00404-023-07271-7.
  • Römer T. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice. Arch Gynecol Obstet. 2018;298(4):747–753. doi: 10.1007/s00404-018-4864-8.
  • Xholli A, Filip G, Previtera F, et al. Modification of endometrioma size during hormone therapy containing dienogest. Gynecol Endocrinol. 2020;36(6):545–549. doi: 10.1080/09513590.2019.1703942.
  • Angioni S, Pontis A, Malune ME, et al. Is dienogest the best medical treatment for ovarian endometriomas? Results of a multicentric case control study. Gynecol Endocrinol. 2020;36(1):84–86. doi: 10.1080/09513590.2019.1640674.
  • Techatraisak K, Hestiantoro A, Soon R, et al. Impact of long-term dienogest therapy on quality of life in asian women with endometriosis: the prospective non-interventional study ENVISIOeN. Reprod Sci. 2022;29(4):1157–1169. doi: 10.1007/s43032-021-00787-w.
  • Murji A, Biberoğlu K, Leng J, et al. Use of dienogest in endometriosis: a narrative literature review and expert commentary. Curr Med Res Opin. 2020;36(5):895–907. doi: 10.1080/03007995.2020.1744120.
  • Lee J, Park HJ, Yi KW. Dienogest in endometriosis treatment: a narrative literature review. Clin Exp Reprod Med. 2023;50(4):223–229. doi: 10.5653/cerm.2023.06128.
  • Buggio L, Lazzari C, Monti E, et al. “Per vaginam” topical use of hormonal drugs in women with symptomatic deep endometriosis: a narrative literature review. Arch Gynecol Obstet. 2017;296(3):435–444. doi: 10.1007/s00404-017-4448-z.
  • Razzi S, Luisi S, Calonaci F, et al. Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis. Fertil Steril. 2007;88(4):789–794. doi: 10.1016/j.fertnstert.2006.12.077.